Grifols Worldwide Operations Limited

Bayer Healthcare LLC

Grifols Therapeutics Inc.

Thomas Barnett

David A Ross

Clark Qun Pan

John E Murphy

Deqian Wang

Jonathan S Strauss

Baisong Mei

Hendri Tjandra

Jianmin Chen

Liang Tang

Jiang Tang

Deqian Wamg

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM

Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived IgM and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products.

Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Factor VIII conjugates

The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.

von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto

This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

Site-directed modification of FVIII

Growing community of inventors

Chapel Hill, NC, United States of America

Thomas Barnett